CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2EJ7ukh
via IFTTT